Table 1.
Pertinent Laboratory Findings
| Date | Total Bilirubin/Direct Bilirubin (mg/dl) | ALP(U/L) | ALT(U/L) | AST (U/L) | INR | Albumin (g/dl) | Scr (mg/dl) | CD4+ Count (cells/mm3) | HIV RNA (copies/ml) |
|---|---|---|---|---|---|---|---|---|---|
| 2009 | |||||||||
| September 4 | 1.1/NA | 77 | 21 | 21 | NA | 4.2 | 1.22 | 304 | < 75 |
| December 4a | 4.7/NA | 1051 | 439 | 438 | 1.4 | NA | 1.32 | NA | NA |
| December 11 | 14.3/NA | 1049 | 312 | 283 | NA | 3.4 | 1.32 | NA | NA |
| 2010 | |||||||||
| January 8 | 16.7/15.6 | 1474 | 228 | 293 | 1.5 | 3.1 | NA | 167 | 50283 |
| January 28 | 24.5/19.9 | 1702 | 277 | 476 | 1.4 | 1.9 | 1.06 | 164 | 33945 |
| February 25 | 14.4/11.9 | 924 | 86 | 148 | 1.34 | 1.4 | 3.09 | NA | NA |
| March 29b | 17.2/13.5 | 2757 | 169 | 308 | 1.27 | 1.8 | 1.31 | 192 | 53853 |
| April 9c | 25.3/21.1 | 1290 | 120 | 201 | 1.54 | 1.4 | 2.52 | 101 | 52 |
| April 16 | 23.0/17.9 | 1948 | 159 | 538 | 1.42 | 1.2 | 2.19 | 126 | < 50 |
| May 3 | 40.5/31.8 | 1087 | 204 | 314 | NA | 2.5 | 2.61 | NA | NA |
| May 18 | 31.1/27.2 | 601 | 142 | 248 | 1.67 | 2.1 | 4.60 | 336 | < 50 |
| June 1 | 45.7/40.5 | 1138 | 106 | 233 | 1.29 | 2.7 | 4.23 | NA | < 50 |
ALP alkaline phosphatase; ALT alanine aminotransferase; AST aspartate aminotransferase; INR international normalized ratio, Scr = serum creatinine; HIV = human immunodeficiency virus; NA = not available.
Normal ranges are as follows: total bilirubin 0.1–1.0 mg/dl; direct bilirubin 0.0–0.2 mg/dl; ALP 37–116 U/L; ALT 6–41 U/L; AST 9–34 U/L; INR albumin 3.7–4.7 g/dl; Scr 0.56–1.16 mg/dl; CD4+ count 334–1556 cells/mm3.
a
First evaluation of liver dysfunction; all antiretroviral drugs discontinued.
b
Raltegravir + enfuvirtide started.
c
Maraviroc started.